Saturday, 25 May 2024
Monday, 04 Mar 2024 12:00 am

Acne Medication Market is expected to reach US$ 11,802.29 million by 2030

Acne medication market estimated to cross US$ 11,802.29 million by 2030 | Insights by acne type, distribution channel, and formulation

By The Insight Partners

Topical Medication Segment to Hold Larger Acne Medication Market Share During 2022–2030

According to our new research study on "Acne Medication Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 7,774.56 million in 2022 to US$ 11,802.29 million by 2030. The market is further anticipated to record a CAGR of 5.40% from 2022 to 2030. Moreover, acne medication market trends include the upsurge in the need for organic and natural treatments. However, side effects associated with acne medication limit the market growth.

Key factors driving the acne medication market growth include the increasing prevalence of severe acne problems and the launch of novel drugs. Innovations in pharmaceuticals, including topical and systemic medications, have fundamentally reshaped treatment approaches for acne. In October 2023, Crown Therapeutics, a branch of Crown Laboratories, added two new PanOxyl products—PanOxyl Clarifying Exfoliant with 2% salicylic acid and PanOxyl Adapalene 0.1% gel—to its dermatologist-endorsed and award-winning PanOxyl range. In September 2023, Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, announced the accessibility of WINLEVI (clascoterone cream 1% w/w) in Canada. For patients aged 12 or above, WINLEVI is the first and only androgen receptor inhibitor recommended for the topical treatment of acne vulgaris, or acne.

Acne Medication Market, by Region, 2022 (%)

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/brochure/TIPRE00004587

Source: The Insight Partners Analysis

Novel drug launches also include advanced formulations with improved efficacy, enhanced safety profiles, and reduced side effects, catering to the evolving needs of individuals seeking effective acne management. According to a statement released in October 2023 by Bausch Health Companies Inc. and its dermatology business—Ortho Dermatologics—the US Food and Drug Administration (FDA) approved the New Drug Application for CABTREO topical gel composed of 1.2%, 0.15%, and 3.1% clindamycin phosphate, adapalene, and benzoyl peroxide, respectively. This is a topical treatment indicated for acne vulgaris in patients aged 12 or older. CABTREO is the first and only topical triple combination acne therapy approved by the FDA, which is offered in a fixed-dose form. The company aims to make this gel available for patients in Q1 2024.

The introduction of novel medications, such as retinoids, anti-androgens, and immune modulators, further expands the therapeutic options available for healthcare professionals and individuals dealing with acne. The continuous introduction of new drugs stimulates competition, fosters innovation, and encourages research and development investments within the dermatological pharmaceutical industry. The heightened focus on personalized and targeted treatment approaches for treating acne forms a foundation for the advent of novel drugs to improve patient outcomes and satisfaction. Thus, the launch of novel drugs significantly contributes to the acne medication market growth.

On the other hand, many traditional and systemic acne treatments, including oral antibiotics, retinoids, and hormonal therapies, are associated with a range of potential adverse effects, including skin dryness, irritation, photosensitivity, gastrointestinal discomfort, and, in rare cases, more severe systemic side effects. These potential adverse reactions have raised concerns among patients and healthcare providers, leading to hesitance in the adoption of certain acne medications, particularly for long-term use. Side effects also result in the lack of treatment adherence, as individuals may opt to discontinue or avoid specific medications due to intolerable or undesirable side effects. Consequently, consumers show an inclination toward advanced formulations and treatment modalities that prioritize efficacy while minimizing adverse reactions, which indicates a constant need for novel and better-tolerated acne medications. Thus, side effects associated with acne medication limit the market growth.

The acne medication market analysis has been carried out by considering the following segments: therapeutic class, formulation, type, acne type, and distribution channel. Based on therapeutic class, the market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. In terms of formulation, the market is bifurcated into topical medication and oral medication. The acne medication market, by usage, is divided into prescription medicine and over-the-counter medicine. Based on acne type, the market is bifurcated into non-inflammatory acne and inflammatory acne. Based on distribution channel, the acne medication market is classified into pharmacies and drug stores, retail stores, and e-commerce.

Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc., GSK Plc, Viatris Inc, Somar Sapi De CV, Carnot Technologies, and Italmex SA are a few key companies profiled in the acne medication market report. The companies have been implementing organic strategies (such as product launches and product approvals) and inorganic strategies (such as expansions, collaborations, and partnerships) to secure growth in the market. For instance, in September 2023, Cosmo Pharmaceuticals NV (Ireland) and Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals (Mumbai), announced signing distribution and licensing arrangements for the distribution of Winlevi (1% clascoterone cream) in South Africa and Europe. The agreements state that Glenmark will get sole rights to market Winlevi in 15 EU nations (Sapin, Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, and Sweden), as well as in South Africa and the UK, via Cassiopea, a Cosmo subsidiary.

The report segments the acne medication market as follows:

The retinoid segment held the largest acne medication market share, based on therapeutic class, in 2022 and the same segment is anticipated to register a significant CAGR in the market during 2022–2030. Retinoids, which can be only bought with a doctor's prescription, contain vitamin A as a primary ingredient; their function is similar to retinol but they are far more potent and more successful in treating acne.

Based on formulation, the acne medication market is classified into topical medication and oral medication. The topical medication segment held the largest share of the acne medication market in 2022. The same segment is further anticipated to record a significant CAGR in the market from 2022 to 2030. Topical formulations play a vital role in managing and treating acne, offering targeted delivery of active ingredients directly to the affected skin areas.

Based on type, the acne medication market is classified into prescription medicines and over-the-counter medicines. The prescription medicines segment held the largest market share in 2022. Dermatologists or healthcare providers typically prescribe medications after a thorough assessment of the individual's acne type, severity, and responsiveness to previous treatments.

The acne medication market, by distribution channel, is segmented into retail stores, pharmacies and drug stores, and others based on mode. In 2022, the pharmacies and drug stores segment held the largest market share.

In terms of geography, the scope of the acne medication market report encompasses North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). The acne medication market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

The Insight Partners :    https://www.theinsightpartners.com

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
© The News and Media Division of The Insight Partners 2024 | All Rights Reserved | Privacy Policy